Home Stocks Chinese regulators accept Zai Lab application for KarXT (ZLAB:NASDAQ)
Stocks

Chinese regulators accept Zai Lab application for KarXT (ZLAB:NASDAQ)

by Deidre Salcido
written by Deidre Salcido 0 comments
Image 1689585487.jpg

JHVEPhoto

Chinese regulators have accepted Zai Lab’s (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and trospium chloride, for the treatment of schizophrenia in adults.

Zai Lab (NASDAQ:ZLAB) has an exclusive license from Bristol-Myers’ (BMY

Deidre Salcido

You may also like

‘In their last days, our parents changed their will’: They left me $250,000,...

Biggest stock movers Friday: DOCU, PTON, and more

Has Tesla stock hit bottom? Here’s what the options market is saying.

ZIM Integrated Shipping extends losses despite Q4 beat; analyst sees ‘downward trajectory’

Wholesale inflation flattens out in February in another sign of easing inflation

ConnectM Technology Solutions delists from Nasdaq (CNTM:NASDAQ)

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.

About Us

Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.

Facebook Twitter Youtube Linkedin Instagram

Jeffrey Christian: Gold, Silver, PGMs in 2025; Plus Precious Metals Facts vs. Fiction

Recent Articles

Ethereum Consolidates Since ‘The Big Dump’ – Local Trend Reversal Or Continuation?
Student Loan Bills Rise Due To IDR Processing Freeze
Should Martin and his wife use TFSA to pay down a mortgage?

Featured

Jeffrey Christian: Gold, Silver, PGMs in 2025; Plus Precious Metals Facts vs. Fiction
Ethereum Consolidates Since ‘The Big Dump’ – Local Trend Reversal Or Continuation?
Student Loan Bills Rise Due To IDR Processing Freeze

© 2025 AI Investor Picks – All Rights Reserved

AI Investor Picks
© 2025 AI Investor Picks - All Rights Reserved
Close